Science and Research

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is the leading cause of cancer-related deaths. Most NSCLC patients are diagnosed with advanced disease and require systemic treatment. Despite emerging advances in chemotherapy and immunotherapy, the prognosis of stage IV patients remains poor. However, the discovery of oncogenic driver mutations including mutations in the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK) and others, characterize a subset of patients with the opportunity of targeted therapies. Fusions between the ALK and echinoderm microtubule-associated protein-like 4 (EML4) are present in

  • Kauffmann-Guerrero, D.
  • Kahnert, K.
  • Huber, R. M.
Publication details
DOI: 10.1007/s40265-020-01445-2
Journal: Drugs
Work Type: Review
Location: CPC-M
Disease Area: LC
Partner / Member: KUM
Access-Number: 33226527

DZL Engagements

chevron-down